Peptides / Recovery and repair

Natural fragment · 34 amino acids · 4,118 Da

Teriparatide (PTH 1-34)

ApprovedNot banned in sport

Teriparatide (Forteo) is the active part of parathyroid hormone, approved in the US and EU for osteoporosis in selected patients. Most studies tested it on bone, and studies in people also tracked pain. PepBank shows 1,667 results on teriparatide from 292 studies in people, and 1,039 from animal and lab studies. The strongest evidence is a randomized trial in people. Data as of 2026-10-30.

Also known as Forsteo, Forteo, PTH(1-34), Teriparatide, rhPTH(1-34)

34 amino acids, from first to last0 changed amino acids

Evidence level: Large trials in people1,667 of 2,709 results come from studies in people, including randomized trials.

Results in people

1,667

62% of 2,709 results

Results in animals

997

37% of 2,709 results

Results in lab cells

2% of 2,709 results

From computer models

under 1% of 2,709 results

Overview

Teriparatide (PTH 1-34) at a glance

What it is	Natural fragment, 34 amino acids
Approval	Approved in the US and EU (Forteo)
In sport	Not listed as banned by WADA
Studies	484 studies with results. 430 of them gave teriparatide, with 2,709 results. 1,667 in people997 in animals42 in lab cells3 from computer models
Best study in people	Randomized controlled trial with 578 people (2012)
Clinical trials	168 registered: 15 active or planned, 60 with posted results
Community use	The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients.

The science

What is teriparatide?

The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients.

Amino acids in one chain

The history of teriparatide

1974
The oldest paper on teriparatide in PepBank is from 1974.
2002November
A registered trial of teriparatide started (NCT00051558).

Teriparatide (PTH 1-34) structure and chemistry

The key facts about the molecule. Long codes are in the closed section below.

Sequence, 34 amino acidsFrom the first amino acid to the last

S1VS−EI5QLMHN10LG+KHL15NSM−E+R20V−EWL+R25+K+KLQ−D30VHNF

Darker means more water-repelling+ and − show charge in the body

Structure

Teriparatide (PTH 1-34) is a natural fragment of 34 amino acids, with no ring, no changed amino acids.

Formula

C₁₈₁H₂₉₁N₅₅O₅₁S₂

Molecular weight

4,118 g/mol

CAS number

52232-67-4

Targets

Parathyroid hormone 1 receptor (gene PTH1R): agonistEvidence: IUPHAR/BPS curated receptor assay dataParathyroid hormone 2 receptor (gene PTH2R): agonistEvidence: IUPHAR/BPS curated receptor assay data

Development

Eli Lilly and Company. Highest phase: past the trial stage (see status).

Identifiers

PubChem 16133850, UNII 10T9CSU89I, DrugBank DB06285, UniProt P01270

Full sequence, SMILES and InChIKey

InChIKey
OGBMKVWORPGQRR-UMXFMPSGSA-N

SMILES
CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC3=CNC4=CC=CC=C43)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC5=CNC=N5)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC6=CC=CC=C6)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CO)N

See charge, composition and 3D structure on the Scientific page

The evidence

What teriparatide studies show

Results grouped by what the studies measured. Each card shows where its results come from.

Large trials in people1,667 of 2,709 results come from studies in people, including randomized trials.

Bones and joints

2,228 results · 1,286 in people · 913 animal · 26 lab

In patients with osteoporosis and existing spinal fractures, weekly teriparatide reduced new spinal fractures compared with placebo. The Journal of clinical endocrinology and metabolism, 2012

Top results

In patients with osteoporosis and existing spinal fractures, weekly teriparatide reduced new spinal fractures compared with placebo. (The Journal of clinical endocrinology and metabolism, 2012)
In patients with hypoparathyroidism, blood calcium stayed similar with PTH and calcitriol plus calcium. (The Journal of clinical endocrinology and metabolism, 2003)
In patients with hypoparathyroidism, urine calcium was normal with PTH but above normal with calcitriol. (The Journal of clinical endocrinology and metabolism, 2003)

Pain

62 results · 62 in people

Teriparatide and risedronate produced similar proportions of women with reduced worst back pain at 6 months. Osteoporosis international, 2012

Top results

Teriparatide and risedronate produced similar proportions of women with reduced worst back pain at 6 months. (Osteoporosis international, 2012)
In women with osteoporosis, teriparatide reduced moderate or severe back pain versus placebo. (Current medical research and opinion, 2005)
After hip fracture, pain after the movement test was lower with teriparatide than risedronate. (The Journal of bone and joint surgery. American volume, 2016)

Daily life and fitness

31 results · 31 in people

After hip fracture, patients completed the movement test faster with teriparatide than risedronate. The Journal of bone and joint surgery. American volume, 2016

Top results

After hip fracture, patients completed the movement test faster with teriparatide than risedronate. (The Journal of bone and joint surgery. American volume, 2016)
After hip fracture, quality of life scores were similar with teriparatide and risedronate. (The Journal of bone and joint surgery. American volume, 2016)
In osteoporosis patients undergoing spinal deformity surgery, teriparatide improved EQ-5D scores compared with denosumab. (Osteoporosis international, 2025)

Salt, water and minerals

30 results · 30 in people

In children with hypoparathyroidism, blood calcium did not differ significantly between PTH 1‑34 and calcitriol with calcium and cholecalciferol. The Journal of clinical endocrinology and metabolism, 2010

Top results

In children with hypoparathyroidism, blood calcium did not differ significantly between PTH 1‑34 and calcitriol with calcium and cholecalciferol. (The Journal of clinical endocrinology and metabolism, 2010)
In children with hypoparathyroidism, urine calcium did not differ significantly between PTH 1‑34 and calcitriol with calcium and cholecalciferol. (The Journal of clinical endocrinology and metabolism, 2010)
After thyroidectomy, hypocalcemia occurred less often with teriparatide than standard care. (The Journal of clinical endocrinology and metabolism, 2016)

Kidneys and bladder

27 results · 24 in people · 3 animal

In osteoporosis patients, serum phosphate was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72. Calcified tissue international, 2016

Top results

In osteoporosis patients, serum phosphate was lower with teriparatide than with placebo at weeks 4, 24, 48, and 72. (Calcified tissue international, 2016)
In children, kidney filtration stayed normal and did not differ between PTH 1‑34 and calcitriol with calcium and cholecalciferol. (The Journal of clinical endocrinology and metabolism, 2010)
In hypoparathyroidism patients, once-daily PTH reduced urine calcium excretion compared with calcitriol and calcium. (JAMA, 1996)

Weight and appetite

15 results · 6 in people · 9 animal

In women with osteopenia, teriparatide reduced marrow fat from baseline at 6 months. Climacteric, 2016

Top results

In women with osteopenia, teriparatide reduced marrow fat from baseline at 6 months. (Climacteric, 2016)
In women with anorexia nervosa, weight changed similarly with teriparatide and placebo. (The Journal of clinical endocrinology and metabolism, 2014)
In women with osteopenia, teriparatide did not change abdominal fat composition. (Climacteric, 2016)

All 484 teriparatide studies by area Open the Scientific page

Key teriparatide studies

Studies in people come first, then studies in animals and in the lab.

People
Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk
Nakamura et al. 2012 · The Journal of clinical endocrinology and metabolism · 578 people · cited by 204
6 results
People
Efficacy of generic teriparatide and alendronate in Chinese postmenopausal women with osteoporosis: a prospective study
Li et al. 2022 · Archives of osteoporosis · 573 people · cited by 18
8 results
People
Study of twice-weekly injections of Teriparatide by comparing efficacy with once-weekly injections in osteoporosis patients: the TWICE study
Sugimoto et al. 2019 · Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 553 people · cited by 29
4 results
People
Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial
Langdahl et al. 2017 · Lancet (London, England) · 432 people · cited by 360
7 results
People
Teriparatide or alendronate in glucocorticoid-induced osteoporosis
Saag et al. 2007 · The New England journal of medicine · 428 people · cited by 569
5 results

All 484 Teriparatide (PTH 1-34) studies

Teriparatide clinical trials

ClinicalTrials.gov lists 168 trials of teriparatide. 15 are active or planned, and 60 have posted results. PepBank does not show trial results.

Solid bars are dates that happened. Hatched bars are planned dates. Data from ClinicalTrials.gov.

Study to Evaluate the Safety and Efficacy of BA058 (Abaloparatide) for Prevention of Fracture in Postmenopausal Women

Phase 3completed2,463 people

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

Phase 4completed1,366 people

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

Phase 3completed712 people

All 80 Teriparatide (PTH 1-34) trials

Status and safety

Is teriparatide approved?

FDA

United States

Approved

An approved medicine contains it.

EMA

European Union

Approved

An approved medicine contains it.

WADA

Sport

Not banned

Not on the 2026 Prohibited List.

Yes. Approved in the US and EU (Forteo). The FDA label for Forteo says: “The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients” Not listed as banned by WADA.

Laws and labels change, so check the regulator for the current status.

Teriparatide side effects and safety

PepBank has 209 safety results from studies of teriparatide. 168 of them come from studies in people.

Safety results from studies (209)

High blood calcium occurred more often with teriparatide than alendronate in glucocorticoid-induced osteoporosis. (The New England journal of medicine, 2007)
After hip fracture, mildly high calcium was more frequent with teriparatide than risedronate. (The Journal of bone and joint surgery. American volume, 2016)
In men with glucocorticoid-induced osteoporosis, adverse events were similar with teriparatide and risedronate. (Journal of bone and mineral research, 2013)
In women with atypical femur fractures, adverse events did not differ between immediate and delayed teriparatide treatment. (Osteoporosis international, 2018)
Repeated high urinary calcium led four people on teriparatide and three on placebo to stop treatment. (The Journal of clinical endocrinology and metabolism, 2007)
In patients with osteoporosis, adverse events occurred more often with teriparatide than placebo but were generally mild and tolerable. (The Journal of clinical endocrinology and metabolism, 2012)
In patients with osteoporosis, twice-weekly teriparatide caused fewer adverse drug reactions than once-weekly treatment. (Osteoporosis international, 2019)
In women with osteoporosis, rhPTH and elcatonin were well tolerated. (Chinese medical journal, 2013)
In postmenopausal women with osteoporosis after bisphosphonates, nasopharyngitis was reported less often with teriparatide than romosozumab. (Lancet, 2017)
Elevated predose calcium was more common with teriparatide than alendronate. (Arthritis and rheumatism, 2009)
In osteoporosis patients receiving either teriparatide regimen, no serious adverse events were reported. (Journal of bone and mineral metabolism, 2024)
In patients with osteoporosis receiving the teriparatide sequences, no serious adverse events were reported. (Journal of bone and mineral metabolism, 2025)
Adverse events occurred in 86.7% of teriparatide recipients and 86.1% of placebo recipients. (Calcified tissue international, 2014)
In patients with osteoporosis, RGB-10 and reference teriparatide had comparable safety profiles. (Osteoporosis international, 2019)
Adding teriparatide caused more reported nausea than HRT alone. (Journal of bone and mineral research, 2006)
In osteoporosis patients receiving weekly hPTH, researchers found no serious adverse effects. (Osteoporosis international, 1999)
Adverse event rates did not differ significantly between teriparatide and elcatonin. (Chinese medical journal, 2009)
In women with osteoporosis, adverse event rates did not differ between rhPTH and elcatonin. (Zhonghua nei ke za zhi, 2010)
In women with osteoporosis, all teriparatide treatments were well tolerated. (The Journal of clinical endocrinology and metabolism, 2010)
In patients with hip fractures, adverse event frequency did not differ significantly between teriparatide and placebo. (Clinical orthopaedics and related research, 2016)
In women with osteoporosis, both teriparatide and alendronate were well tolerated. (The Journal of clinical endocrinology and metabolism, 2002)
In Asian women with osteoporosis, adverse event rates were similar with teriparatide and calcitonin. (Current medical research and opinion, 2006)
In women after lumbar fusion, instrumentation-related complications were similar with teriparatide and zoledronate. (World neurosurgery, 2022)
In postmenopausal osteoporosis, adverse reaction rates did not differ significantly between rhPTH (1-34) plus vitamin K2 and vitamin K2 alone. (Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 2025)

See every safety result on the Scientific page

Doses studied (40 shown)

The doses that these studies used. They are not recommendations.

Dose as reported	Class	Species	Route	Duration	Design	Source
56.5 μg once weekly	Human	human	subcutaneous	72 weeks	Randomized trial in people · n = 578	Nakamura 2012
20 µg daily	Human	human	subcutaneous	48 weeks	Randomized trial in people · n = 573	Li 2022
28.2 μg twice weekly	Human	human	Not reported	48 weeks	Randomized trial in people · n = 553	Sugimoto 2019
20 microg once daily	Human	human	Not reported	18 months	Randomized trial in people · n = 428	Saag 2007
20 μg once daily	Human	human	subcutaneous	12 months	Randomized trial in people · n = 415	Langdahl 2017
20 microg/day	Human	human	Not reported	18 months	Randomized trial in people · n = 277	Langdahl 2009
20 μg once daily	Human	human	subcutaneous	52 weeks	Randomized trial in people · n = 250	Hagino 2019
56.5 µg once weekly	Human	human	Not reported	72 weeks	Randomized trial in people · n = 180	Tanaka 2021
20 μg every day	Human	human	Not reported	78 weeks	Randomized trial in people · n = 171	Malouf-Sierra 2017
20 μg/day	Human	human	subcutaneous	6 months	Randomized trial in people · n = 157	Bhandari 2016
20 μg	Human	human	Not reported	18 months	Randomized trial in people · n = 79	Orwoll 2014
40 μg daily	Human	human	subcutaneous injection	9 months	Randomized trial in people · n = 69	Tsai 2019
40 microg daily	Human	human	injection	8 weeks	Randomized trial in people · n = 68	Aspenberg 2010
20 μg once daily	Human	human	subcutaneous	12 months	Randomized trial in people · n = 58	Dempster 2012
20 μg daily	Human	human	Not reported	2 months	Randomized trial in people · n = 50	Ledin 2017
40 microg daily	Human	human	subcutaneous	12 months	Randomized trial in people · n = 43	Finkelstein 1998
20 mcg	Human	human	Not reported	6 months	Randomized trial in people · n = 41	Cohen 2020
20 µg/day	Human	human	subcutaneous	8 weeks	Randomized trial in people · n = 34	Sim 2020
20 μg	Human	human	subcutaneous	6 months	Randomized trial in people · n = 21	Fazeli 2014
20 μg daily	Human	human	subcutaneous	12 months	Randomized trial in people · n = 20	Rastogi 2019
20 µg daily	Human	human	subcutaneous	52 weeks	Randomized trial in people	Cosman 2011
20 μg/day	Human	human	Not reported	18 months	Randomized trial in people	Hadji 2012
37 microg daily	Human	human	sc	begun at month 6 of a 30-month study	Randomized trial in people	Finkelstein 2006
20, 30, or 40 microg daily	Human	human	transdermal	6 months	Randomized trial in people	Cosman 2010
20 μg daily	Human	human	subcutaneous	18 months	Randomized trial in people	Walker 2013
20 microg daily	Human	human	subcutaneous	6 months	Randomized trial in people	Sethi 2008
20 μg daily or cyclically	Human	human	Not reported	2 years daily vs 4 years cyclic	Randomized trial in people	Ganapathy 2023
20 microg	Human	human	Not reported	median 19 months	Randomized trial in people · n = 1,085	Genant 2005
20 μg/day	Human	human	Not reported	26 weeks	Randomized trial in people · n = 171	Aspenberg 2016
20 μg/day	Human	human	Not reported	18 months	Randomized trial in people · n = 92	Glüer 2013
20 µg daily	Human	human	Not reported	24 weeks	Randomized trial in people	Prasad 2026
20 and 40 microg/d	Human	human	Not reported	Up to 12 months	Randomized trial in people · n = 2,074	Miller 2007
20 or 40 microg/day	Human	human	Not reported	median 19 months	Randomized trial in people · n = 1,637	Chen 2006
20 or 40 μg daily, pooled	Human	human	injection	Not reported	Randomized trial in people · n = 1,637	Harvey 2015
20 or 40 microg daily	Human	human	subcutaneous	Median 19 months	Randomized trial in people · n = 1,620	Dawson-Hughes 2007
40 microg daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 1,096	Lindsay 2009
20 microg daily	Human	human	subcutaneous	Not reported	Randomized trial in people · n = 1,085	Lindsay 2009
20 μg/day	Human	human	self-injection	Median 19 months	Randomized trial in people · n = 1,085	Krege 2012
20 or 40 mug once daily	Human	human	subcutaneous	Median 20 months	Randomized trial in people · n = 558	Uusi-Rasi 2005
20 and 40 mug daily	Human	human	subcutaneous	Median 20 months	Randomized trial in people · n = 558	Uusi-Rasi 2005

From the community

How people use it

What people report online. It comes from forums and guides, not from studies.

Community-reported. Not tested in trials.

The official US label describes prescription use. These regimens are label information and are not community practice.

Reported routines and cautions

What people use it for

The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients.S1

Reported regimens

Regimens that community sources report for Teriparatide. Community-reported, not tested in trials.
Context	Route	Amount	How often	How long	Agreement	Sources
Adults with a labeled osteoporosis indicationOfficial label dosing of an approved product	subcutaneous injectionThe label specifies the thigh or abdominal region.	20 mcg per dose	once daily	Use beyond 2 years during a lifetime requires continued or renewed high fracture risk.	Official US prescribing information.	S1

Cautions

The label warns about osteosarcoma risk in predisposed patients, hypercalcemia, and orthostatic hypotension.S1

Community sources

S1US Teriparatide prescribing information (opens in a new tab)dailymed.nlm.nih.gov

Gaps

This record contains one official label source. This review did not assess additional community sources. The record does not reproduce every administration instruction.

Questions and more

Ask a question about teriparatide

The answer links to every study it uses.

What does the evidence say about teriparatide?Is teriparatide tested in people?Compare with BPC-157 Compare with Thymosin beta-4 (human)

Sources

Database: PepBank data for teriparatide (data version 308560)
Regulator: FDA status record
Regulator: EMA status record
Regulator: WADA status record
Trial registry: ClinicalTrials.gov
Community: community sources (forums and guides), as summarized in the PepBank community file

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Ask your AI about teriparatide

Teriparatide (PTH 1-34)

ApprovedNot banned in sport

Also known as Forsteo, Forteo, PTH(1-34), Teriparatide, rhPTH(1-34)

What it is

Natural fragment, 34 amino acids

Approval

Approved in the US and EU (Forteo)

In sport

Not listed as banned by WADA

Studies

484 studies with results. 430 of them gave teriparatide, with 2,709 results.
1,667 in people997 in animals42 in lab cells3 from computer models

Best study in people

Randomized controlled trial with 578 people (2012)

Clinical trials

168 registered: 15 active or planned, 60 with posted results

Community use

The active N-terminal fragment of parathyroid hormone, approved for osteoporosis in selected patients.

Dose as reported

Class

Species

Route

Duration

Design

Source

56.5 μg once weekly

Human

human

subcutaneous

72 weeks

Randomized trial in people · n = 578

Nakamura 2012

20 µg daily

Human

human

subcutaneous

48 weeks

Randomized trial in people · n = 573

Li 2022

28.2 μg twice weekly

Human

human

Not reported

48 weeks

Randomized trial in people · n = 553

Sugimoto 2019

20 microg once daily

Human

human

Not reported

18 months

Randomized trial in people · n = 428

Saag 2007

20 μg once daily

Human

human

subcutaneous

12 months

Randomized trial in people · n = 415

Langdahl 2017

20 microg/day

Human

human

Not reported

18 months

Randomized trial in people · n = 277

Langdahl 2009

20 μg once daily

Human

human

subcutaneous

52 weeks

Randomized trial in people · n = 250

Hagino 2019

56.5 µg once weekly

Human

human

Not reported

72 weeks

Randomized trial in people · n = 180

Tanaka 2021

20 μg every day

Human

human

Not reported

78 weeks

Randomized trial in people · n = 171

Malouf-Sierra 2017

20 μg/day

Human

human

subcutaneous

6 months

Randomized trial in people · n = 157

Bhandari 2016

20 μg

Human

human

Not reported

18 months

Randomized trial in people · n = 79

Orwoll 2014

40 μg daily

Human

human

subcutaneous injection

9 months

Randomized trial in people · n = 69

Tsai 2019

40 microg daily

Human

human

injection

8 weeks

Randomized trial in people · n = 68

Aspenberg 2010

20 μg once daily

Human

human

subcutaneous

12 months

Randomized trial in people · n = 58

Dempster 2012

20 μg daily

Human

human

Not reported

2 months

Randomized trial in people · n = 50

Ledin 2017

40 microg daily

Human

human

subcutaneous

12 months

Randomized trial in people · n = 43

Finkelstein 1998

20 mcg

Human

human

Not reported

6 months

Randomized trial in people · n = 41

Cohen 2020

20 µg/day

Human

human

subcutaneous

8 weeks

Randomized trial in people · n = 34

Sim 2020

20 μg

Human

human

subcutaneous

6 months

Randomized trial in people · n = 21

Fazeli 2014

20 μg daily

Human

human

subcutaneous

12 months

Randomized trial in people · n = 20

Rastogi 2019

20 µg daily

Human

human

subcutaneous

52 weeks

Randomized trial in people

Cosman 2011

20 μg/day

Human

human

Not reported

18 months

Randomized trial in people

Hadji 2012

37 microg daily

Human

human

begun at month 6 of a 30-month study

Randomized trial in people

Finkelstein 2006

20, 30, or 40 microg daily

Human

human

transdermal

6 months

Randomized trial in people

Cosman 2010

20 μg daily

Human

human

subcutaneous

18 months

Randomized trial in people

Walker 2013

20 microg daily

Human

human

subcutaneous

6 months

Randomized trial in people

Sethi 2008

20 μg daily or cyclically

Human

human

Not reported

2 years daily vs 4 years cyclic

Randomized trial in people

Ganapathy 2023

20 microg

Human

human

Not reported

median 19 months

Randomized trial in people · n = 1,085

Genant 2005

20 μg/day

Human

human

Not reported

26 weeks

Randomized trial in people · n = 171

Aspenberg 2016

20 μg/day

Human

human

Not reported

18 months

Randomized trial in people · n = 92

Glüer 2013

20 µg daily

Human

human

Not reported

24 weeks

Randomized trial in people

Prasad 2026

20 and 40 microg/d

Human

human

Not reported

Up to 12 months

Randomized trial in people · n = 2,074

Miller 2007

20 or 40 microg/day

Human

human

Not reported

median 19 months

Randomized trial in people · n = 1,637

Chen 2006

20 or 40 μg daily, pooled

Human

human

injection

Not reported

Randomized trial in people · n = 1,637

Harvey 2015

20 or 40 microg daily

Human

human

subcutaneous

Median 19 months

Randomized trial in people · n = 1,620

Dawson-Hughes 2007

40 microg daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 1,096

Lindsay 2009

20 microg daily

Human

human

subcutaneous

Not reported

Randomized trial in people · n = 1,085

Lindsay 2009

20 μg/day

Human

human

self-injection

Median 19 months

Randomized trial in people · n = 1,085

Krege 2012

20 or 40 mug once daily

Human

human

subcutaneous

Median 20 months

Randomized trial in people · n = 558

Uusi-Rasi 2005

20 and 40 mug daily

Human

human

subcutaneous

Median 20 months

Randomized trial in people · n = 558

Uusi-Rasi 2005

Context

Route

Amount

How often

How long

Agreement

Sources

Adults with a labeled osteoporosis indicationOfficial label dosing of an approved product

subcutaneous injectionThe label specifies the thigh or abdominal region.

20 mcg per dose

once daily

Use beyond 2 years during a lifetime requires continued or renewed high fracture risk.

Official US prescribing information.

Teriparatide (PTH 1-34)

Teriparatide (PTH 1-34) at a glance

What is teriparatide?

The history of teriparatide

Teriparatide (PTH 1-34) structure and chemistry

What teriparatide studies show

Bones and joints

Pain

Daily life and fitness

Salt, water and minerals

Kidneys and bladder

Weight and appetite

Key teriparatide studies

Teriparatide clinical trials

Is teriparatide approved?

Teriparatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about teriparatide

Related peptides

Sources

Teriparatide (PTH 1-34)

Teriparatide (PTH 1-34) at a glance

What is teriparatide?

The history of teriparatide

Teriparatide (PTH 1-34) structure and chemistry

What teriparatide studies show

Bones and joints

Pain

Daily life and fitness

Salt, water and minerals

Kidneys and bladder

Weight and appetite

Key teriparatide studies

Teriparatide clinical trials

Is teriparatide approved?

Teriparatide side effects and safety

How people use it

What people use it for

Reported regimens

Cautions

Community sources

Ask a question about teriparatide

Related peptides

Sources